Loss of heterozygosity in oral cancer

Kasamatsu, Atsushi; Uzawa, Katsuhiro; Usukura, Katsuya; Koike, Kazuhiko; Nakashima, Daisuke; Ishigami, Takashi; Fushimi, Kazuaki; Ogawara, Katsunori; Shiiba, Masashi; Tanzawa, Hideki

doi:10.1016/s1348-8643(11)00027-9

Cited by 17 publications

(14 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These histologic response rates compare favorably with other chemoprevention trials . LOH is thought to facilitate tumorigenesis via the monoallelic inactivation of tumor suppressor genes . The results of the LOH evaluation before and after gel treatment showed that a local drug delivery strategy significantly reduces LOH .…”

Section: Advances In Drug Delivery Systemssupporting

confidence: 57%

Polymeric drug delivery systems for intraoral site‐specific chemoprevention of oral cancer

Desai

2017

J Biomed Mater Res

View full text Add to dashboard Cite

Oral cancer is among the most prevalent cancers in the world. Moreover, it is one of the major health problems and causes of death in many regions of the world. The traditional treatment modalities include surgical removal, radiation therapy, systemic chemotherapy, or a combination of these methods. In recent decades, there has been significant interest in intraoral site-specific chemoprevention via local drug delivery using polymeric systems. Because of its easy accessibility and clear visibility, the oral mucosa is amenable for local drug delivery. A variety of polymeric systems-such as gels, tablets, films, patches, injectable systems (e.g., millicylindrical implants, microparticles, and in situ-forming depots), and nanosized carriers (e.g., polymeric nanoparticles, nanofibers, polymer-drug conjugates, polymeric micelles, nanoliposomes, nanoemulsions, and polymersomes)-have been developed and evaluated for the local delivery of natural and synthetic chemopreventive agents. The findings of in vitro, ex vivo, and in vivo studies and the positive outcome of clinical trials demonstrate that intraoral site-specific drug delivery is an attractive, highly effective and patient-friendly strategy for the management of oral cancer. Intraoral site-specific drug delivery provides unique therapeutic advantages when compared to systemic chemotherapy. Moreover, intraoral drug delivery systems are self-administrable and can be removed when needed, increasing patient compliance. This article covers important aspects and advances related to the design, development, and efficacy of polymeric systems for intraoral site-specific drug delivery. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1383-1413, 2018.

show abstract

Section: Advances In Drug Delivery Systemssupporting

confidence: 57%

Polymeric drug delivery systems for intraoral site‐specific chemoprevention of oral cancer

Desai

2017

J Biomed Mater Res

View full text Add to dashboard Cite

show abstract

“…Loss of heterozygosity (LOH) occurs in a somatic cell upon loss of genomic material specifically within the only remaining copy of a functional allele. LOH patterns have been found in OSCC samples at various loci across all chromosomes, except X and Y . Most notably, LOH has been observed on chromosomal arms 3p, 9p, 13q, and 17p at the earliest stages of oral carcinogenesis .…”

Section: Molecular Markersmentioning

confidence: 99%

Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory

Dionne

Warnakulasuriya

Zain

et al. 2014

Intl Journal of Cancer

206

161

View full text Add to dashboard Cite

Despite commendable progress in the prevention, detection, and treatment of a wide variety of solid tumor types, oral squamous cell carcinoma (OSCC) remains a significant health burden across the globe. OSCC carcinogenesis involves accumulation of genetic alterations that coincide with the multistep malignant transformation of normal oral epithelium. OSCC is often first diagnosed at late stages of the disease (advanced regional disease and/or metastasis). Delayed diagnosis precludes successful treatment and favorable outcomes. In clinical practice, opportunities exist to identify patients with oral potentially malignant disorders (OPMDs), which precede the development of cancer. This review addresses the current status of laboratory and clinical research on OPMDs, with emphasis on leukoplakia and erythroplakia. OSF is also presented, though there is a paucity of published studies on this disorder. We focus on findings that could translate into earlier diagnosis and more efficacious treatment of those lesions with significant malignant potential. We explore how markers of OPMD malignant transformation might be implemented into current diagnostic practice to help clinicians objectively stratify patients into treatment/follow-up groups according to relative risk. We provide an overview of recently concluded and ongoing OPMD chemoprevention trials. We describe laboratory OPMD models that can be used to not only to reveal the genetic and molecular intricacies of oral cancer but also to develop novel screening methods and therapeutic approaches. Finally, we call for targeted screening programs of at-risk populations in order to facilitate diagnosis and treatment of OPMD and early OSCC.Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with 600,000 new cases reported annually. 1,2 Approximately half of these cases present as squamous cell carcinoma on the lip or within the oral cavity. 3 While the detection and treatment of most malignancies has improved over the last several decades, the prognosis associated with oral squamous cell carcinoma (OSCC) has remained unchanged. [4][5][6] As a result, more than 120,000 deaths can be attributed to OSCC per annum. 7 Oral cancer does not currently satisfy criteria for a screenable disease, 8 however, theory 9 suggests that most cases are preceded by asymptomatic clinical lesions collectively referred to as oral potentially malignant disorders (OPMDs). 10 Herein, we review basic and clinical research on OPMDs and suggest possible approaches to effectively address this public health burden. Particular attention is placed on how understanding OPMD might translate into earlier diagnosis and more efficacious treatment. Nomenclature and EpidemiologyThere are several OPMDs that precede the development of OSCC. Those most commonly encountered are erythroplakia

show abstract

“…Analysis of loss of heterozygosity (LOH) is one of the common methods used to molecular study of premalignant lesions and was previously used for detection of molecular abnormalities in HNSCC . As a result of this analysis, almost 6000 variants in all cellular groups were observed.…”

Section: Resultsmentioning

confidence: 99%

Whole exome sequencing approach to analysis of the origin of cancer stem cells in patients with head and neck squamous cell carcinoma

Salazar-García

Pérez‐Sayáns

García‐García

et al. 2018

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

Loss of heterozygosity in oral cancer

Cited by 17 publications

References 77 publications

Polymeric drug delivery systems for intraoral site‐specific chemoprevention of oral cancer

Polymeric drug delivery systems for intraoral site‐specific chemoprevention of oral cancer

Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory

Whole exome sequencing approach to analysis of the origin of cancer stem cells in patients with head and neck squamous cell carcinoma

Contact Info

Product

Resources

About